天境生物 IMAB 深 沪
等待开盘 04-01 09:30:00 美东时间
4.63
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.63
- 总市值 5.32亿
- 52周最高 6.79
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.595
- 委 比 0.00%
- 总股本 1.15亿
- 历史最高 85.40
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.595
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
BRIEF-Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting March 18 (Reuters) - InflaRx NV IF0G.F : INFLARX ANNOUNCES LATE-BREAKER ORAL PRESENTATION ON VILOBELIMAB PHASE 3 RESULTS IN PYODERMA GA
03-18 19:57
BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab March 5 (Reuters) - Cytodyn Inc CYDY.PK : CYTODYN CLOSES $17.5 MILLION FINANCING TO FUND CONTINUED DEVELOPMENT OF LERONLIMAB Source text: ID:nGNX91D0Rt Further company coverage: CYDY.PK (( Reuters.Briefs@thomson
03-05 21:31
BRIEF-Kyowa Kirin Announces Discontinuation Of Rocatinlimab Clinical Trials
BRIEF-Kyowa Kirin Announces Discontinuation Of Rocatinlimab Clinical Trials March 3 (Reuters) - Kyowa Kirin Co Ltd 4151.T : KYOWA KIRIN ANNOUNCES DISCONTINUATION OF ROCATINLIMAB CLINICAL TRIALS Source text: ID:nGNX1Pcm15 Further company coverage: 4151.T (( Reuters.Briefs@thomsonreuters.com ;))
03-03 21:07
BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial
BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial Feb 23 (Reuters) - MacroGenics Inc MGNX.O : MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN LINNET TRIAL MACROGENICS INC: U. S. FOOD AND DRUG ADMINISTRATION (FDA) HAS PLACED A PARTIA
02-24 07:31
BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab
BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab Feb 2 (Reuters) - Skye Bioscience Inc SKYE.O : SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RESULTS FOR NIMACIMAB IN COMBINATION WITH SEMAGLUTIDE SKYE BIOSCIENCE INC - 22.3% WEIGHT LOSS AT 52
02-02 20:26
BRIEF-Sanofi's Amlitelimab Confirms Potential In Atopic Dermatitis
BRIEF-Sanofi's Amlitelimab Confirms Potential In Atopic Dermatitis Jan 23 (Reuters) - Sanofi SA SASY.PA : AMLITELIMAB CONFIRMS ITS POTENTIAL IN ATOPIC DERMATITIS AQUA AND ESTUARY STUDIES TO REPORT RESULTS IN H2 2026 AMLITELIMAB MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN SHORE STUDY Source text: ID
01-23 14:13
刚刚！天境生物与之科控股达成超长效创新药合作
（来源：药研网） 2025年12月26日，天境生物宣布，与之江实验室科技控股有限公司(以下简称"之科控股")签署合作协议，携手应用之江实验室科技成果，推进包括生...
2025-12-26 17:29
BRIEF-Participant Death Reported in Pfizer Hemophilia Trial, Letter Shows
Dec 23 (Reuters) - Pfizer Inc PFE.N: PARTICIPANT IN LONG-TERM EXTENSION TRIAL STUDYING MARSTACIMAB IN PEOPLE LIVING WITH HEMOPHILIA A/B WITH/WITHOUT INHIBITORS PASSED AWAY IN DEC Further company cover...
2025-12-24 00:17
BRIEF-Pfizer Says Does Not Anticipate Any Impact To Safety For Patients Treated With Approved Marstacimab
Dec 23 (Reuters) - Pfizer Inc PFE.N: PFIZER: SAFETY AND WELL-BEING OF PARTICIPANTS IN OUR CLINICAL TRIALS REMAIN OUR HIGHEST PRIORITY, AND WE ARE COMMITTED TO TRANSPARENCY PFIZER: DOES NOT ANTICIPATE ...
2025-12-24 00:05
BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike
Dec 12 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR MNEXSPIKE, FOR PREVENTION OF COVID-19 IN PEOPLE FROM 12 YEARS OF AGE EMA'S CHMP: RECOMMENDED CHANGE TO EXTEN...
2025-12-12 23:11
